Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
home:publications:heil_autoimmunity_2016 [04.30.2016]
joyful [Poster - Immunostimulation: a treatment innovation in chronic inflammatory and autoimmune disorders] updated PDF file title
home:publications:heil_autoimmunity_2016 [05.01.2016] (current)
joyful [Abstract] text of abstract broken into two paragraphs
Line 15: Line 15:
  
  
-Due to the increasingly complex and comorbid nature of chronic inflammatory and auto-immune disorders, treatment of these conditions calls for a new approach, as many patients do not respond to current treatment modalities. Seven years ago, we began exploring a novel immuno-modulating monotherapy to volunteer patients using a retargeted drug, olmesartan medoxomil, which, when dosed more frequently than usual, stimulates the innate immune system by acting as a VDR nuclear receptor agonist. Patients who had previously failed to respond to long term “standard of care,” “feel better” palliative, immune suppressive therapy associated with significant relapse rates were no longer interested in defensively managing their conditions with unscientifically based expectations of recovery. Instead, these patients engaged in long-term novel offensive positioning and effective treatment which involved “feeling worse at first” accompanied by synergistic immune stimulation,​ having a full scientifically-based intent and expectation of cure. Sixty-two (62) volunteer patients from a nurse practitioner practice in Arizona were admitted as participants in this observational cohort between 2008 and 2012.  Conventional clinical symptoms were monitored using a consistent 10-point self-reporting scale at each encounter. Self-reported symptoms monitored include: insomnia, depression, incontinence,​ fatigue, irritability,​ pain, and loss of focus. Objective laboratory data was collected to measure various health parameters. ​ Emotional support was offered to assist in subject retention, utilizing both collaboration on an Internet discussion site and in person local support meetings. Many symptoms and diagnoses responded well to this novel immunostimulation. Case-series data will be presented with case details available upon request.+Due to the increasingly complex and comorbid nature of chronic inflammatory and auto-immune disorders, treatment of these conditions calls for a new approach, as many patients do not respond to current treatment modalities. Seven years ago, we began exploring a novel immuno-modulating monotherapy to volunteer patients using a retargeted drug, olmesartan medoxomil, which, when dosed more frequently than usual, stimulates the innate immune system by acting as a VDR nuclear receptor agonist. Patients who had previously failed to respond to long term “standard of care,” “feel better” palliative, immune suppressive therapy associated with significant relapse rates were no longer interested in defensively managing their conditions with unscientifically based expectations of recovery. Instead, these patients engaged in long-term novel offensive positioning and effective treatment which involved “feeling worse at first” accompanied by synergistic immune stimulation,​ having a full scientifically-based intent and expectation of cure.  
 + 
 +Sixty-two (62) volunteer patients from a nurse practitioner practice in Arizona were admitted as participants in this observational cohort between 2008 and 2012.  Conventional clinical symptoms were monitored using a consistent 10-point self-reporting scale at each encounter. Self-reported symptoms monitored include: insomnia, depression, incontinence,​ fatigue, irritability,​ pain, and loss of focus. Objective laboratory data was collected to measure various health parameters. ​ Emotional support was offered to assist in subject retention, utilizing both collaboration on an Internet discussion site and in person local support meetings. Many symptoms and diagnoses responded well to this novel immunostimulation. Case-series data will be presented with case details available upon request.
  
 {{tag>​posters Trudy_Heil 2016}} {{tag>​posters Trudy_Heil 2016}}
  
home/publications/heil_autoimmunity_2016.txt · Last modified: 05.01.2016 by joyful
© 2015, Autoimmunity Research Foundation. All Rights Reserved.